US Wegovy Supply to Expand 'Gradually': Novo Nordisk CEO

Show Transcript
Bloomberg Nov 3, 2023 00:54 · 16.9k Views

Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company’s weight loss medications will “be lowered somewhat” through the end of the year as the company plans to be “gradually expanding and bringing more and more product to the US.” He speaks on "Bloomberg The Open."

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Transcript

  • 00:00 I don't really need to say that obviously demand for Waco V is just skyrocketing right now.
  • 00:04 So let's talk a little bit about supply.
  • 00:06 We're clearly, we've seen issues specifically in the
  • 00:09 US where you've limited starter doses.
  • 00:12 When should we start to see some of those supply constraints start to ease?
  • 00:18 Yeah, thanks for having me today.
  • 00:19 You're right.
  • 00:19 This is a really exciting moment where we see tremendous
  • 00:22 demand for our medicines.
  • 00:24 We have a keen focus on making sure that patients get a good experience.
  • 00:28 So we want to make sure that those who start treatment can also continue treatment
  • 00:31 and that's why we have taken
  • 00:33 the start of doses down to make sure that when you tighten it up you can have a good experience on the maintenance dose.
  • 00:38 We keep increasing our capacity as just explained by the recent upgrade.
  • 00:43 As we look to the future, we'll be gradually expanding and bringing more and more product to the US
  • 00:48 so we can continue this innovation based growth strategy,
  • 00:52 specifically
  • 00:53 how and when I cannot.
  • 00:55 Go into much details about, but you can trust there will be
  • 00:58 more and more supplies coming to the mark.
  • 01:00 Well, Lars, you said previously that in terms of the starter doses, we should expect to see those limits
  • 01:05 stretch into 2024.
  • 01:07 Is that still the timeline?
  • 01:10 Well, we will.
  • 01:12 We see it's a dynamic situation.
  • 01:14 It's obviously also a function of of demand
  • 01:17 how we have to
  • 01:18 handle these starter doses and a function of how we supply.
  • 01:22 So we're not going to specific guidance about it,
  • 01:25 but for the remainder of the year, you'll see
  • 01:27 the starter doses being
  • 01:29 lowered somewhat.
  • 01:30 And then we'll decide
  • 01:31 in a dynamic fashion when we have supplies and we see what the demand is
  • 01:36 when we can gradually bring more starter doses in, but they'll there are more and more products coming all the time.